Maze Therapeutics, Inc. (MAZE), a clinical-stage biopharmaceutical company, on Tuesday announced the appointment of Misbah Tahir as chief financial officer with immediate effect.
Tahir has over 20 years of financial and strategic experience in the biopharmaceutical industry. Tahir had previously held senior finance positions at Dermira, Inc. Onyx Pharmaceuticals, Inc.
The company said its solid balance sheet and projected cash runway into the second half of 2027, along with its unique precision genetics platform, advancing clinical pipeline, and disciplined development strategy, position the company to deliver significant value to both patients and shareholders.
On Friday, Maze Therapeutics closed trading 1.54% higher at $14.49 on the Nasdaq.
For comments and feedback contact: editorial@rttnews.com
Business News
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.